Argenica Therapeutics Limited (ASX:AGN)
Australia
· Delayed Price · Currency is AUD 0.210
+0.010 (5.00%)
Mar 10, 2026, 1:54 PM AEST
Argenica Therapeutics Revenue
Argenica Therapeutics had revenue of 626.74K AUD in the half year ending December 31, 2025, a decrease of -73.36%. This brings the company's revenue in the last twelve months to 1.01M, down -67.31% year-over-year. In the fiscal year ending June 30, 2025, Argenica Therapeutics had annual revenue of 3.21M with 23.70% growth.
Revenue (ttm)
1.01M
Revenue Growth
-67.31%
P/S Ratio
25.52
Revenue / Employee
n/a
Employees
n/a
Market Cap
25.69M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NeuroScientific Biopharmaceuticals | 317.91K |
| Algorae Pharmaceuticals | -26.16K |
| Noxopharm | 2.68M |
| Patrys | 100.38K |
| Avecho Biotechnology | 1.24M |
| Neurotech International | 7.07M |
| EZZ Life Science Holdings | 61.40M |
| Entropy Neurodynamics | 1.58M |